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ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia. Until recently, AD 
is managed by relieving the cognitive symptoms without addressing one of the 
purportedly fundamental causes of the disease which is the formation of the amyloid 
plaques. The deposition and aggregation of P-amyloid are key events in the onset, 
progression and pathogenesis of AD. Thus one of the emerging strategies in treating 
AD is to inhibit the enzyme responsible for the formation of amyloid plaques, which 
is P-site amyloid cleaving enzyme (BACE-1). Endophytes are currently viewed as an 
outstanding source of bioactive natural products and may provide BACE-1 inhibitors 
as potential drug candidates for the treatment of AD. A novel bioactive compound, 
F70HAB16 was successfully isolated from a local endophytic strain and was found to 
inhibit the BACE-1 enzyme in vitro (IC5o=13 pM). Oral treatment with 5 mg/kg of 
F70HAB16 for 14 days in scopolamine-induced memory deficit mice model was 
found to restore memory impairment caused by scopolamine in the radial arm maze 
and Morris water maze (MWM) tasks. The same treatment was found to improve 
spatial memory and learning in MWM tasks in a transgenic mice model of AD 
(B6.129TG) carrying the human APP-Swedish mutation (K670N/M671L). Analysis 
of the blood plasma and brain tissue of the transgenic mice revealed that the 
expression of amyloidogenic proteins decreased following treatment with the BACE- 
1 inhibitor. Oxidative stress may play a significant but yet undefined role in the 
development of AD. It was found that the administration of 5 mg/kg of the 
F70HAB16 reduced the lipid peroxidation index and restored the antioxidant 
activities of catalase, superoxide dismutase, glutathione reductase and glutathione in 
the brain tissue of the scopolamine-induced mice model. The treatment with 5 mg/kg 
of F70HAB16 also redressed the level of nitric oxide in the scopolamine-induced 
mice. Hence F70HAB16 may prove to be beneficial in the treatment of AD by 
alleviating the oxidative stress associated with this disease. Furthermore, F70HAB16 
also demonstrated neuroprotective properties on the cholinergic system of the 
scopolamine-induced mice. Finally, metabolomics study of the blood plasma revealed 
that F70HAB16 down-regulated sphingolipids such as dihydrosphingosine, 
phytosphingosine and C16-sphinganin. These metabolites were recently proposed as 
biomarkers for AD since they were found to be up-regulated in the blood plasma of 
AD patients.
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